Positive Health Online
Your Country
Research: KORNITZER and co-workers,
Listed in Issue 104
Abstract
KORNITZER and co-workers, School of Public Health, Brussels Free University, Belgium, cververi@ulb.ac.be, have conducted a nested case-control study of selenium and cancer mortality.
Background
The aim of the study was to assess the predictive power of serum selenium levels with regard to cancer mortality in a large sample of the Belgian population.
Methodology
A total of 201 cases of death from cancer were randomly selected from all cancer deaths during a 10-year mortality follow-up of a large sample of the total Belgian population were matched for age and gender with 603 controls. Conditional logistic regression for both univariate and multivariate analyses using tertile distribution of serum selenium was carried out.
Results
The odds ratio for the lowest versus highest tertile of serum selenium in men was 2.2, whereas in women it was 0.8 and not significant. Beside selenium, beta-carotene intake and smoking are independent predictors for cancer mortality in men but not in women.
Conclusion
In this study, serum selenium was found to be a predictor of deaths from cancer in men but not in women.
References
Kornitzer M, Valente F,de Bacquer D, Neve J, de Backer G. Serum selenium and cancer mortality: a nested case-control study within an age-and sex-stratified sample of the Belgian adult population. European Journal of Clinical Nutrition 58 (1): 98-104, Jan 2004.
Comment
The above results demonstrates the critical role of selenium in prostate cancer risk and mortality. Pity that some of the most bioavailable forms of selenium may be banned if the current EU Supplement Directive comes into effect.